United Kingdom· GB-APID-45529111000001101
Tepezza 500mg powder for concentrate for solution for infusion vials
A medicinal product containing teprotumumab, registered in United Kingdom by Amgen Ltd.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Teprotumumab
- Manufacturer
- Amgen Ltd
- Country
- United Kingdom (GB)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 2
- gtin8715131030667
- gtin08715131030667
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Teprotumumab in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumTepezza 500 mgAmgen Europe
- SwitzerlandTepezza 500 mg, Pulver für ein Konzentrat zur Herstellung einer InfusionslösungAmgen Switzerland AG
- CzechiaTEPEZZAAmgen Europe B.V., Breda
- SpainTEPEZZA 500 MG POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSIONAmgen Europe B.V.
- FinlandTEPEZZAAmgen Europe B.V.
- IrelandTEPEZZA 500 mg powder for concentrate for solution for infusionAmgen Europe B.V.,
- IcelandTepezzaAmgen Europe B.V.*
- PolandTepezzaAmgen Europe B.V.
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Tepezza
- Norway · Tepezza
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/edf6602a-33ae-4fb4-9b5e-245827d90b13 GET /v1/drugs/edf6602a-33ae-4fb4-9b5e-245827d90b13?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "45529111000001101",
"desc": "Tepezza 500mg powder for concentrate for solution for infusion vials (Amgen Ltd)",
"form": "Powder for solution for infusion",
"vpid": "45531711000001102",
"source": "dmd",
"vtm_id": "840398004",
"strength": "500 mg",
"substance": "Teprotumumab",
"ingredient": "Teprotumumab",
"supplier_code": "3303701000001100"
}See everything about teprotumumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.